Related Experiment Video
Updated: Aug 7, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled
Hertzel C Gerstein1, Shun-Fu Lee1, Guillaume Paré1,2
11Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.
Glucagon-like peptide-1 receptor agonist dulaglutide lowered NT-proBNP and GDF-15 levels. These biomarkers were linked to major adverse cardiovascular events (MACE), suggesting a potential mechanism for dulaglutide
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Biomarker Research
Background:
- The glucagon-like peptide-1 receptor agonist dulaglutide demonstrated cardiovascular benefits in the REWIND trial.
- Understanding the relationship between biomarkers, dulaglutide treatment, and major adverse cardiovascular events (MACE) is crucial for elucidating its mechanism of action.
Purpose of the Study:
- To investigate the association of changes in protein biomarkers and metabolites with dulaglutide treatment and MACE.
- To explore potential mechanistic links between dulaglutide's cardiovascular protective effects and specific biomarker alterations.
Main Methods:
- A post hoc analysis of the REWIND trial involving plasma samples from participants with and without MACE.
- Analysis of 2-year changes in 19 protein biomarkers and 135 metabolites using linear and logistic regression models.
- Identification of biomarkers associated with both dulaglutide treatment and MACE.
Main Results:
- Dulaglutide was associated with a reduced 2-year rise in N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and growth differentiation factor 15 (GDF-15) compared to placebo.
- Increased levels of NT-proBNP and GDF-15 from baseline were significantly associated with an increased risk of MACE.
- Specific metabolite changes (2-hydroxybutyric acid and threonine) were also linked to dulaglutide treatment.
Conclusions:
- Dulaglutide treatment is associated with favorable changes in NT-proBNP and GDF-15.
- Elevated NT-proBNP and GDF-15 levels are predictive of MACE, suggesting these biomarkers may mediate dulaglutide's cardiovascular benefits.
More Related Videos
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...